EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial

Sarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, Yizhou Zhao, Devin Schellenberg, Haley Clark, Benjamin Mou, Mitchell Liu, Fred Hsu, Tanya Berrang, Siavash Atrchian, Alanah Bergman und 5 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2025.01.031 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Sarah Baker und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, Canada; Department of Surgery, Division of Radiation Oncology, BC Cancer, Surrey, Canada. Electronic addre…. Hauptthemen laut MEDLINE: Lung Neoplasms, Radiosurgery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE/OBJECTIVES: There are limited data on outcomes in patients with ultracentral pulmonary oligometastases treated with SABR. The purpose of this study was to determine whether ultracentral location was prognostic for toxicity and survival. MATERIAL AND METHODS: Oligometastatic lung lesions treated on the single-arm phase 2 SABR-5 trial were retrospectively stratified into 2 cohorts: ultracentral tumors (UC), defined as planning target volume overlap or direct tumor abutment to the proximal bronchial tree, esophagus, great vessels, or heart, and nonultracentral tumors. Cohorts were compared with respect to grade ≥ 2 toxicity, progression-free survival (PFS), and overall survival (OS). RESULTS: In total, 41 patients with 45 ultracentral metastases and 93 patients with 172 nonultracentral metastases underwent SABR. The most common primary histologies were colorectal (30%), lung (13%), and renal (13%), and these did not differ between groups. Patients with UC had a lower median PFS of 5.8 months compared with 15.8 months in patients with non ultracentral tumors (P < .001). OS was also worse in the UC cohort: median 29.0 months versus not yet reached (P < .001). On multivariable regression, UC remained prognostic for worse PFS (hazard ratio 2.18, P = .004) and OS (hazard ratio 3.45, P < .001). Groups had similar rates of local tumor control. Patients with UC had higher 2-year cumulative incidence of polymetastatic progression: 69.2% versus 31.4% (P < .001). The 2-year cumulative incidence of grade ≥ 2 toxicity was 14.6% for patients with UC and 9.8% for patients with nonultracentral tumors (P = .74). There were no grade 4 or 5 toxicities. CONCLUSIONS: In this prospective patient cohort, SABR for ultracentral tumor had low toxicity rates and good local control. However, ultracentral location was an adverse prognostic feature for survival. This finding should be validated with larger studies and may be a factor when weighing the benefit versus risk of SABR in patients with pulmonary oligometastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsRadiosurgeryHumansMaleFemaleMiddle AgedAgedRetrospective StudiesProgression-Free SurvivalAdultKidney NeoplasmsAged, 80 and overColorectal NeoplasmsTreatment Outcome

Autor:innen und Institutionen

  • University of British Columbia, Vancouver, Canada; Department of Surgery, Division of Radiation Oncology, BC Cancer, Surrey, Canada. Electronic address: sarah.baker1@bccancer.bc.ca.
  • University of British Columbia, Vancouver, Canada.
  • University of British Columbia, Vancouver, Canada; Department of Surgery, Division of Radiation Oncology, BC Cancer, Surrey, Canada.
  • University of British Columbia, Vancouver, Canada; Department of Surgery, Division of Radiation Oncology, BC Cancer, Kelowna, Canada.
  • University of British Columbia, Vancouver, Canada; Department of Surgery, Division of Radiation Oncology, BC Cancer, Vancouver, Canada.
  • University of British Columbia, Vancouver, Canada; Department of Surgery, Division of Radiation Oncology, BC Cancer, Abbotsford, Canada.

Zitieren

APA

Baker, S., Leclerc, C., Atmanspacher-Wirth, H., Zhao, Y., Schellenberg, D., Clark, H., Mou, B., Liu, M., Hsu, F., Berrang, T., Atrchian, S., Bergman, A., Chng, N., Matthews, Q., Chang, J. S., Tyldesley, S., & Olson, R. (2025). The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.01.031

Vancouver

Baker S, Leclerc C, Atmanspacher-Wirth H, Zhao Y, Schellenberg D, Clark H, et al. The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.01.031

BibTeX
@article{Baker2025,
  author = {Baker, Sarah and Leclerc, Curtis and Atmanspacher-Wirth, Hanna and Zhao, Yizhou and Schellenberg, Devin and Clark, Haley and Mou, Benjamin and Liu, Mitchell and Hsu, Fred and Berrang, Tanya and Atrchian, Siavash and Bergman, Alanah and Chng, Nick and Matthews, Quinn and Chang, Jee Suk and Tyldesley, Scott and Olson, Robert},
  title = {The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2025.01.031}
}
Kostenlos starten →